Digital self-help for eating disorders: early value assessmentStatus:In developmentProgramme:Health technology evaluationExpected publication date: 13 November 2025
School-based interventions: physical and mental health and wellbeing promotionStatus:In developmentExpected publication date: TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years [ID6297]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]Status:In developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years ID6510Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC